DocWire News Editors

DocwireNews

In high-income countries, the greatest cause of irreversible severe vision loss is neovascular age-related macular degeneration (nAMD). While vascular endothelial growth factor (VEGF) inhibitors are a widely used treatment, it is unknown what lifetime anti-VEGF treatment outcomes are.According to a study, anti-VEGF treatment preserved useful visual acuity in close to 20% of patients during the remainder of their lifetime.The researchers used real-world cohort data of 3,192 patients with nAMD treated at eye clinics in Australia, New Zealand, and Switzerland; collectively, the patients had more than 67,000 clinic visits. The primary outcome was visual acuity in both eyes over the course of their remaining lifetime.The mean remaining lifetime among the patients was 11 years, during which time about 12% of patients (n=371; 95% confidence interval [CI], 345-400) retained driving visual acuity and 15% (n=463; 95% CI, 434-495) retained reading visual acuity in at least one eye. About 82% of patients (n=2,629; 95% CI, 2,590-2,660) dropped out. Factors associated with better long-term outcomes were younger age at baseline and more injections during the first year of treatment.&ldquo;This is a remarkable outcome compared with outcomes without intervention, which lead to legal blindness within three years of disease onset in 80% of those affected. These findings underline the public health necessity of providing anti-VEGF treatment to persons in need,&rdquo; the study authors concluded.

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Latest News

Lifetime Outcomes of Anti-VEGF Treatment in Neovascular AMD

Ophthalmology

In high-income countries, the greatest cause of irreversible severe vision loss is neovascular age-related macular degeneration (nAMD). While vascular endothelial growth ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe